Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.44 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.44 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24372009 | 0.92 | SLC6A1 (0.41) | TPSAB1TPSD1TPSG1FAAHITGB3 | |
| SCHEMBL1201466 | 0.90 | HTR4 (0.39) | TPSAB1TPSD1TPSG1FAAHITGB3 | |
| SCHEMBL28307203 | 0.86 | ITGB3 (0.39) | TPSAB1TPSD1TPSG1FAAHITGB3 | |
| SCHEMBL381520 | 0.83 | TSHR (0.48) | TPSAB1TPSD1TPSG1FAAHITGB3 | |
| SCHEMBL4800701 | 0.83 | CYP1A2 (0.44) | EPHX2 | |
| SCHEMBL23971408 | 0.82 | EPHX2 (0.44) | FAAHEPHX2 | |
| SCHEMBL24541945 | 0.82 | SLC6A1 (0.43) | TPSAB1TPSD1TPSG1ITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL382253 | 0.81 | TSHR (0.47) | TPSAB1TPSD1TPSG1FAAHITGB3 | |
| SCHEMBL31240257 | 0.81 | EPHX2 (0.47) | FAAHEPHX2 | |
| SCHEMBL31240157 | 0.81 | EPHX2 (0.47) | FAAHEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070112022-A1 | Piperidine derivatives as ccr5 receptor modulators | ASTRAZENECA AB (SE) | 2007-05-17 | — | — | US | disclosed |
| EP-1654229-B1 | PIPERIDINE DERIVATIVES AS CCR5 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-05-09 | — | — | EP | disclosed |
| EP-1654229-A1 | PIPERIDINE DERIVATIVES AS CCR5 RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005009959-A1 | PIPERIDINE DERIVATIVES AS CCR5 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112022-A1 | Piperidine derivatives as ccr5 receptor modulators | CCR5, CCR2, CCR6 | TPSAB1 1582/4885TPSD1 1444/4885TPSG1 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.